Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with anti-PD-1 therapy in patients diagnosed with locally advanced, unresectable esophageal cancer.

Trial Details

NCT ID
NCT06173986
Phase
PHASE1 / PHASE2
Sponsor
Shanghai Chest Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • PD-1inhibitor
  • nab-paclitaxel + cisplatin
  • Radiotherapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age between 18 and 75 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Clinical stage meeting the criteria of T1N+M0 or T2-4aN0-3M0 based on the 8th UICC-TNM classification.
  • Ineligibility for surgical resections due to patients' unwillingness for surgery, technically unresectable disease, or being medically unfit for su…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →